How Composer keeps AI-enabled MIDD workflows scientific and under your control
Physiologically based Biopharmaceutics Modeling (PBBM) Reveals a Low Dissolution-related Bioequivalence Risk for Immediate-Release Amlodipine Tablets
A conservative BCS class III classification was recently proposed for amlodipine based on inconclusive permeability evidence.
Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin
Collaboration will apply Turin to explore mechanistic QSP model structures at scale and bring insights to development decisions where traditional modeling timelines have limited their use
AI in MIDD: From Hype to Practical Application
Everyone wants to incorporate AI into model-informed drug development (MIDD), but the open question is how to do so while maintaining scientific rigor, transparency, and regulatory confidence.
Simulations Plus Announces Completion of Acquisition by Altaris
The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations Plus shareholder received $18.50 in cash per share. As a result of the completion of the transaction, Simulations Plus has become a privately held company, and its common stock will no longer trade on the Nasdaq Global Select Market.
Importance of Early Model Development and Data Strategy
Regulatory perspectives increasingly emphasize the value of integrating modeling early in the drug development process rather than applying it retrospectively.
Dose Optimization of Cefazolin for Pediatric Patients with Renal Impairment Using Physiologically Based Pharmacokinetic Modeling (PBPK) in GastroPlus
Cefazolin is a first-generation cephalosporin antibiotic widely used for the treatment and prophylaxis of bacterial infections in both adult and pediatric populations.
Physiologically Based Pharmacokinetic Modelling and Dose Optimization of Tedizolid in Paediatric Patients
Tedizolid is a next-generation oxazolidinone antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Understanding Pharmacokinetic Variability of Pomalidomide: A Physiologically Based Pharmacokinetic Analysis of Disease-Related Physiology, Ethnicity, Hepatic Impairment, Food Effects, Drug Interactions, and Smoking
Understanding interindividual pharmacokinetic variability and potential for drug interactions is of clinical importance for pomalidomide given its long-term use in patients with relapsed and/or refractory multiple myeloma (RRMM).
Navigating Surfactant Selection in In Vitro Dissolution Testing: Mechanistic Insights and Practical Strategies
In vitro dissolution testing is central to pharmaceutical development, yet it is increasingly challenged by poorly soluble drugs, which account for over 40% of marketed products and up to 90% of new chemical entities, for which dissolution often limits absorption.
Scientists Must Lead the AI Revolution, Not Follow It
One of the more common narratives surrounding AI is the idea that automation will gradually reduce the importance of scientists and technical experts. Personally, I believe the opposite is true.
ADMET Predictor® 14: Expanded bRo5, HTPK, and AI Capabilities
Drug discovery is maturing. Researchers are increasingly focusing on challenging targets, including beyond Rule of 5 (bRo5) compounds, to achieve previously intractable therapeutic opportunities.
Scientific Engines and Regulatory Trust Must Sit at the Center of AI
AI is the buzzword across every industry right now, and the pharma industry is not immune.
Application of Predictive Modeling in the Development of Amorphous Solid Dispersions
Effective modeling and simulation can reduce physical experimental requirements, ASD development risks, and time to market.
Mechanistic Modeling in the Age of AI: Why PBPK Still Anchors Human Dose Prediction
We have an exciting new drug target, we’ve validated the biology, we have a structure, now it’s time to design a compound.
ADMET Predictor® 14 Product Brochure
Predict and build with confidence
Earlier & Faster: Combining ML and HT-PBPK to Accelerate Early Small Molecule Drug Discovery
Accurately predicting the pharmacokinetics (PK) of small-molecule candidates early in discovery can accelerate optimization cycles, reduce animal testing, and improve the quality of compounds advancing toward the clinic.
Everyone Sees AI Differently, and That’s the Challenge
Right now, using AI means something completely different depending on who you ask.
A Curated Benchmark Database for High-Throughput Mechanistic Pharmacokinetic Prediction
The evaluation of a drug candidate's pharmacokinetic (PK) properties, while critical for the success of a drug, has traditionally been excluded from the early drug development process, in large part due to the cost of assays and the difficulty predicting PK properties from structures.
Exploring Avenues of Predicting Drug-Induced Liver Injury
Drug-induced liver injury (DILI) is a major cause of acute liver dysfunction and remains one of the most challenging adverse drug reactions encountered in clinical practice.